Frigate Ventures LP New Position in Novogen Limited (ADR)...

Frigate Ventures LP New Position in Novogen Limited (ADR) (NASDAQ:NVGN)

Frigate Ventures Lp has filled a SC 13G form regarding Novogen Ltd . Filing Link: 000119312515244290. Per Frigate Ventures Lp’s filing, the filler now owns 6.8% of the Health Care-company, holding 28,911,612 shares.

Novogen Limited (ADR) (NASDAQ:NVGN) is a newly disclosed equity position for this institutional investor and the filing was required due to activity on June 24,2015. This most probably shows Frigate Ventures Lp’s confidence and optimism in the future of the company. As a institutional investor with $326.98 million AUM and 5+ professional employees, we have no reason to doubt they didn’t do their homework before buying such a stake.

Novogen Ltd Hedge Funds Ownership

Latest SEC filings show 8 hedge funds and institutional investors own Novogen Ltd. The institutional ownership of the company in Q1 2015 is very low, at 0.14% of the shares outstanding. They increased by 150014 the total shares they hold. As of that quarter these institutional investors owned 231198 shares. A total of 3 funds opened new positions in Novogen Ltd and 2 increased their holdings. There were 2 funds that closed their positions and 1 that reduced them.

Jane Street Group Llc is the most positive institutional investor on Novogen Ltd, with ownership of 56947 shares as of Q1 2015 for less than 0.01% of the fund’s portfolio. Bank Of Montreal is another positive player owning 40000 shares of the company or less than 0.01% of their stocks portfolio. NY Renaissance Technologies Llc have less than 0.01% of their stock portfolio invested in the stock for 103200. Further, Creative Planning disclosed it had purchased a stake worth less than 0.01% of the fund’s stock portfolio in the company. The V8 Credit Suisse Ag was also a notable investor in the firm, owning 21427 shares. Novogen Ltd is less than 0.01% of the fund’s stock portfolio.
Company Profile

Novogen Limited, is an Australia-based biotechnology company. The Company owns two drug technology platforms. The Company targets unmet clinical needs and has therapeutic potential across cancer, degenerative disorders, autoimmune disease and regenerative medicine. The Company aims to enable cytotoxic chemotherapy to eradicate most forms of cancer. The drug technologies include: Super-Benzopyrans and Anti-Tropomyosins. Super-Benzopyrans, possess the ability to kill cancer stem cells, prevent cancer recurrence, potential to become standard of care for first-line therapy across most forms of cancer, and manageable toxicity. Anti-Tropomyosins, drug targeting cancer cell’s micro-filaments, complement the action of used drugs in oncology, and potential to become standard of care in combination with taxanes and vinca alkaloids.
Form 13G is used when the filer owns between 5% and 20% of the company and plans to hold it only as a passive investor. If the filler intend to exert control and if the stake’s size exceeds 20%, then a 13D must be filed. Therefore, activist investors and practices such as: hostile takeovers, company breakups, and other “change of control” events, are not permitted by 13G filers.

Read more: http://www.octafinance.com/frigate-ventures-lp-just-bought-novogen-ltd-stake/90726/#ixzz3eunGQglp​